Acceleron Announces Proposed Public Offering of Common Stock
04 Enero 2016 - 3:58PM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, today announced that it intends to
offer and sell, subject to market and other conditions, $150
million of its common stock in an underwritten public offering. As
part of this offering Acceleron intends to grant the underwriters a
30-day option to purchase up to an additional fifteen percent of
the number of shares sold. All of the shares in the offering are to
be sold by Acceleron.
Morgan Stanley, Leerink Partners LLC and UBS Investment Bank are
acting as joint book-running managers for the offering. JMP
Securities is acting as the lead manager.
Acceleron intends to use the net proceeds from the offering to
conduct clinical trials and associated activities in connection
with ACE-083, Acceleron’s clinical stage therapeutic candidate
designed to promote muscle growth and function in specific,
targeted muscles, and Acceleron’s other potential therapeutic
candidates, including antibodies and proteins from Acceleron’s
IntelliTrapTM platform, to further expand Acceleron’s research and
development efforts, and for general and administrative expenses,
potential future development programs, capital expenditures and
working capital and other general corporate purposes.
The securities described above are being offered by Acceleron
pursuant to its registration statement on Form S-3 filed with the
Securities and Exchange Commission (the “SEC”) on January 4, 2016,
which became effective automatically when it was filed. The
offering will be made only by means of a preliminary prospectus
supplement and accompanying prospectus, copies of which may be
obtained, when available, from Morgan Stanley, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014; Leerink Partners LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA, 02110, or by e-mail at
Syndicate@Leerink.com, or by phone at 800-808-7525, ext. 6142; and
UBS Securities LLC, 1285 Avenue of the Americas, New York, New York
10019, Attention: Prospectus Department, or by phone at
1-888-827-7275. The final terms of the offering will be disclosed
in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in
which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
therapeutic candidates that regulate cellular growth and repair.
The company is a leader in understanding the biology of the
Transforming Growth Factor-Beta (TGF-β) protein superfamily, a
large and diverse group of molecules that are key regulators in the
growth and repair of tissues throughout the human body, and in
targeting these pathways to develop important new medicines.
Acceleron has built a highly productive R&D platform that has
generated innovative clinical and preclinical therapeutic
candidates with novel mechanisms of action. These therapeutic
candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release, including those
relating to the use of proceeds from the sale of common stock, are
forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and
uncertainties include, but are not limited to: the volatility of
our stock price may prevent shares purchased in the offering from
being resold at or above the price paid for them; purchasers of
shares in the offering will suffer immediate and substantial
dilution; we may use the proceeds from the offering in ways that
may not enhance our operating results or the market price of our
common stock; and other risk factors identified from time to time
in the reports we file with Securities and Exchange Commission,
including our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, which are available at
www.sec.gov. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. The forward-looking statements in this press release speak
only as of the date of this document, and we undertake no
obligation to update or revise any of the statements. Our business
is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should
give careful consideration to these risks and uncertainties.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160104006501/en/
Investors:Acceleron PharmaTodd James, 617-649-9393Senior
Director, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
917-570-7340Bmiles@bmccommunications.com
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024